Company news

Scancell Holdings PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Encouraging early efficacy data from ModiFY trial

February 21, 2023

Positive response in COVIDITY trial

February 13, 2023

Issue of Equity

February 8, 2023

Dr Jean-Michel Cosséry appointed as Chairman

February 1, 2023

Licenses Vaccitech technology to advance Modi-2

November 7, 2022

First patient dosed in expansion phase of ModiFY

October 31, 2022

Results for the year ended 30 April 2022

October 28, 2022

Directorate Changes

October 26, 2022

Signs Commercial License Agreement with Genmab

October 25, 2022

Change of Nominated Adviser

October 13, 2022

Preclinical data at the EuroMAbNet Annual Meeting

September 23, 2022

Change of Registered Office

September 6, 2022

First patient dosed in Cohort 2 of the ModiFY

August 16, 2022

Scancell to produce TCB antibodies

June 23, 2022

Phase 2 SCOPE trial of SCIB1 vaccine expanded

June 15, 2022

First patient dosed in Modi-1 Phase 1 trial

June 13, 2022

Change of Registered Holder of Shares

April 12, 2022

Modi-1 Phase 1/2 trial open for recruitment

April 11, 2022

Update on COVIDITY clinical trial

March 29, 2022

Scancell progresses its new anti-glycan mAb

March 17, 2022

Update on COVIDITY Phase 1 clinical trial

January 31, 2022

Interim Results for the 6 months ended 31 Oct 2021

January 26, 2022

First patient dosed in SCIB1 Phase 2 trial

November 19, 2021

Notice of Annual General Meeting

November 1, 2021

Results for the year ended 30 April 2021

October 29, 2021

Extension of CLN Redemption Dates

October 28, 2021

New facilities at The Oxford Science Park

October 19, 2021

First subject dosed in COVIDITY clinical trial

October 5, 2021

PDMR dealing

September 9, 2021

Modi-1 Phase I/II CTA approved by MHRA

August 26, 2021

Scancell selects PharmaJet's Needle-free Systems

August 17, 2021

COVIDITY Phase 1 trial application in SA approved

July 29, 2021

Lindy Durrant appointed CEO of Scancell

July 28, 2021

COVIDITY trial planned in South Africa and UK

June 22, 2021

Appointment of Joint Broker

June 15, 2021

Block listing six monthly return

February 16, 2021

Statement regarding share price movement

February 15, 2021

Update on SCIB2 clinical development partnership

February 3, 2021

Interim Results for the 6 months ended 31 Oct 2020

January 29, 2021

COVID-19 vaccine candidate selected

December 18, 2020

Results of Annual General Meeting

November 17, 2020

Appointment of CMO and Medical Director

November 17, 2020

Result of Adjourned General Meeting

November 5, 2020

Convertible Loan Notes & Total Voting Rights

November 2, 2020

Result of Open Offer and Adjournment of GM

October 29, 2020

Conversion of Convertible Loan Notes

October 26, 2020

Final Results for the year ended 30 April 2020

October 16, 2020

Posting of Circular

October 13, 2020

Proposed investment by Redmile and Open Offer

October 12, 2020

Collaboration to manufacture COVID-19 vaccine

October 2, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 21 decks. Every deck is listed under its year.